Free Trial

Skye Bioscience (SKYE) Competitors

$5.89
-0.07 (-1.17%)
(As of 07/19/2024 08:56 PM ET)

SKYE vs. ARCT, RGNX, IGMS, KALV, REPL, ALMS, CGC, ALEC, CTNM, and YMAB

Should you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Arcturus Therapeutics (ARCT), REGENXBIO (RGNX), IGM Biosciences (IGMS), KalVista Pharmaceuticals (KALV), Replimune Group (REPL), Alumis (ALMS), Canopy Growth (CGC), Alector (ALEC), Contineum Therapeutics (CTNM), and Y-mAbs Therapeutics (YMAB). These companies are all part of the "pharmaceutical products" industry.

Skye Bioscience vs.

Skye Bioscience (NASDAQ:SKYE) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Skye Bioscience has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -81.59%. Arcturus Therapeutics' return on equity of -37.61% beat Skye Bioscience's return on equity.

Company Net Margins Return on Equity Return on Assets
Skye BioscienceN/A -212.28% -120.36%
Arcturus Therapeutics -81.59%-37.61%-23.99%

In the previous week, Arcturus Therapeutics had 3 more articles in the media than Skye Bioscience. MarketBeat recorded 5 mentions for Arcturus Therapeutics and 2 mentions for Skye Bioscience. Arcturus Therapeutics' average media sentiment score of 0.33 beat Skye Bioscience's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Skye Bioscience
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arcturus Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Arcturus Therapeutics has higher revenue and earnings than Skye Bioscience.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Skye BioscienceN/AN/A-$37.65MN/AN/A
Arcturus Therapeutics$169.93M3.77-$29.73M-$3.91-6.08

Skye Bioscience has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.64, indicating that its stock price is 164% more volatile than the S&P 500.

Arcturus Therapeutics received 424 more outperform votes than Skye Bioscience when rated by MarketBeat users. However, 100.00% of users gave Skye Bioscience an outperform vote while only 65.50% of users gave Arcturus Therapeutics an outperform vote.

CompanyUnderperformOutperform
Skye BioscienceOutperform Votes
5
100.00%
Underperform Votes
No Votes
Arcturus TherapeuticsOutperform Votes
429
65.50%
Underperform Votes
226
34.50%

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are held by institutional investors. 0.7% of Skye Bioscience shares are held by company insiders. Comparatively, 13.8% of Arcturus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Skye Bioscience presently has a consensus target price of $19.25, indicating a potential upside of 226.83%. Arcturus Therapeutics has a consensus target price of $68.17, indicating a potential upside of 186.53%. Given Skye Bioscience's higher possible upside, equities analysts plainly believe Skye Bioscience is more favorable than Arcturus Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Skye Bioscience
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Arcturus Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Arcturus Therapeutics beats Skye Bioscience on 11 of the 14 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SKYE vs. The Competition

MetricSkye BiosciencePharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$165.33M$6.76B$4.91B$8.32B
Dividend YieldN/A2.85%5.25%3.96%
P/E RatioN/A17.92148.2918.11
Price / SalesN/A474.072,259.19108.75
Price / CashN/A32.1033.7233.62
Price / Book-34.655.834.854.63
Net Income-$37.65M$141.99M$105.58M$213.97M
7 Day Performance-6.51%1.87%118.11%2.69%
1 Month Performance-24.20%9.78%129.69%8.59%
1 Year PerformanceN/A-2.71%132.09%3.64%

Skye Bioscience Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ARCT
Arcturus Therapeutics
2.1126 of 5 stars
2.11 / 5 stars
$23.79
+1.6%
$68.17
+186.5%
-29.7%$640.67M$169.93M-6.08180Short Interest ↑
News Coverage
RGNX
REGENXBIO
4.5359 of 5 stars
4.54 / 5 stars
$12.58
-2.1%
$38.58
+206.7%
-31.1%$632.94M$90.24M-2.14370Positive News
IGMS
IGM Biosciences
3.5982 of 5 stars
3.60 / 5 stars
$10.74
+0.3%
$17.89
+66.6%
+5.5%$632.14M$2.13M-2.49190News Coverage
Gap Up
KALV
KalVista Pharmaceuticals
3.3333 of 5 stars
3.33 / 5 stars
$14.55
+2.5%
$24.00
+64.9%
+48.0%$621.87MN/A-4.28100
REPL
Replimune Group
4.5844 of 5 stars
4.58 / 5 stars
$9.89
-1.7%
$16.67
+68.5%
-52.4%$617.84MN/A-3.05210Positive News
ALMS
Alumis
0 of 5 stars
0.00 / 5 stars
$12.50
-0.1%
N/AN/A$582.88MN/A0.00N/APositive News
CGC
Canopy Growth
1.1332 of 5 stars
1.13 / 5 stars
$7.13
-1.2%
$4.53
-36.4%
+84.4%$580.77M$220.27M-1.121,029News Coverage
Positive News
ALEC
Alector
4.1422 of 5 stars
4.14 / 5 stars
$5.83
flat
$14.00
+140.1%
-12.7%$561.95M$97.06M-4.22270Positive News
CTNM
Contineum Therapeutics
0 of 5 stars
0.00 / 5 stars
$20.15
-4.2%
$28.00
+39.0%
N/A$518.26M$50M0.0031Positive News
YMAB
Y-mAbs Therapeutics
2.6383 of 5 stars
2.64 / 5 stars
$11.59
-0.9%
$17.86
+54.1%
+76.1%$513.43M$84.82M-23.65150News Coverage
Positive News

Related Companies and Tools

This page (NASDAQ:SKYE) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners